Session » SLE – Treatment Poster II
- 10:30AM-12:30PM
-
Abstract Number: 1548
Anifrolumab in Systemic Lupus Erythematosus. Spanish National Registry in a Real-world Setting
- 10:30AM-12:30PM
-
Abstract Number: 1554
Belimumab Increases SLE Responder Index-4 Response Rates versus Placebo in Early Active Systemic Lupus Erythematosus: A Large Integrated Analysis of Belimumab Trials
- 10:30AM-12:30PM
-
Abstract Number: 1550
CD19 CAR T Cell Therapy Suppresses the Inflammatory Profile of Neutrophils in Systemic Lupus Erythematosus
- 10:30AM-12:30PM
-
Abstract Number: 1546
Characteristics and Treatment Patterns of Patients with Lupus Nephritis: A Retrospective Claims Database Study in the USA
- 10:30AM-12:30PM
-
Abstract Number: 1544
Comparison of Efficacy and Safety Between Belimumab and Telitacicept in the Treatment of Systemic Lupus Erythematosus
- 10:30AM-12:30PM
-
Abstract Number: 1537
Discovery of VENT-03: A Novel Clinical cGAS Inhibitor for the Treatment of SLE and Other Autoimmune Diseases
- 10:30AM-12:30PM
-
Abstract Number: 1541
Effect of Rituximab on Long-term Damage Acquisition in Patients with Systemic Lupus Erythematosus
- 10:30AM-12:30PM
-
Abstract Number: 1539
Effectiveness & Safety of Early versus Late Use of Rituximab in Extra-renal Lupus: Real World Experience from a Tertiary Care Centre
- 10:30AM-12:30PM
-
Abstract Number: 1556
Efficacy and Safety of Anifrolumab Across Organ Domains of Systemic Lupus Erythematosus. A Systematic Review and Meta-Analysis
- 10:30AM-12:30PM
-
Abstract Number: 1542
Efficacy and Safety Results from a Phase 2 Trial of Daxdilimab in Patients with Systemic Lupus Erythematosus
- 10:30AM-12:30PM
-
Abstract Number: 1551
Efficacy of Belimumab on Different Phenotypes of Joint and Skin Manifestations of Systemic Lupus Erythematosus: Preliminary Data from a Multicenter, Nationwide, Cohort of Patients: The BElimumab in Real Life Setting Study-New Joint and Skin (BeRLISS-NeJS)
- 10:30AM-12:30PM
-
Abstract Number: 1547
Hydroxychloroquine and Prednisone Use by Individuals Diagnosed with Systemic Lupus Erythematosus in the TriNetX Research Database
- 10:30AM-12:30PM
-
Abstract Number: 1543
Improvements in BILAG Musculoskeletal and Mucocutaneous Domains at Week 48 in a Phase 2 Double-Blind Placebo-Controlled Trial of ABBV-599 (Elsubrutinib + Upadacitinib Combination) and Upadacitinib Monotherapy for Treatment of Moderately to Severely Active Systemic Lupus Erythematosus
- 10:30AM-12:30PM
-
Abstract Number: 1533
Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, Effectively Depletes Low-Expressing CD20+ B Cells in Preclinical Models of Autoimmune Disease
- 10:30AM-12:30PM
-
Abstract Number: 1552
Kinetics of Mucocutaneous and Musculoskeletal Responses to Deucravacitinibin Patients with Active SLE in the Phase 2 PAISLEY Trial
- 10:30AM-12:30PM
-
Abstract Number: 1532
Not yet on Track: Retrospective Chart Analysis Reveals Physician’s Treatment Approaches in SLE Fall Short of New EULAR Guidance
- 10:30AM-12:30PM
-
Abstract Number: 1538
Patient Reported Outcomes Analyses from AURORA 1 Clinical Trial: Lupus Impact Tracker and LupusPRO
- 10:30AM-12:30PM
-
Abstract Number: 1549
Prescribing Trends for Novel Treatments in Systemic Lupus from 2017 to 2022
- 10:30AM-12:30PM
-
Abstract Number: 1536
Prescription Rates of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Lupus Nephritis: A Comparative Study Across Specialties
- 10:30AM-12:30PM
-
Abstract Number: 1540
Project HOPE: HydrOxychloroquine Adherence ProjEct
- 10:30AM-12:30PM
-
Abstract Number: 1531
Prospective mRNA SARS-CoV-2 Additional Vaccination in Systemic Autoimmune Disease Patients on Immunosuppressive Medications in a Randomized Controlled Trial
- 10:30AM-12:30PM
-
Abstract Number: 1545
Rates of Sustained Complete Renal Response with Long-term Use of Voclosporin in AURORA 2
- 10:30AM-12:30PM
-
Abstract Number: 1553
Safety, Pharmacokinetics, Clinical Efficacy and Exploratory Biomarker Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Enpatoran in Active Systemic and Cutaneous Lupus Erythematosus (SLE/CLE)
- 10:30AM-12:30PM
-
Abstract Number: 1555
Sustained Functional Assessment of Chronic Illness Therapy–Fatigue Response in Patients with SLE Receiving Anifrolumab Alongside Standard Therapy
- 10:30AM-12:30PM
-
Abstract Number: 1534
Use and Safety of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients with Lupus Nephritis and Clinical Indications